Tegoprazan
- Generic Name
- Tegoprazan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O3
- CAS Number
- 942195-55-3
- Unique Ingredient Identifier
- W017G7IF4S
- Background
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. Tegoprazan’s strong and sustained ...
- Indication
用于治疗胃食管反流病、糜烂性食管炎及消化性溃疡等酸相关疾病。
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Incheon St.Mary's Hospital
- Target Recruit Count
- 217
- Registration Number
- NCT04674774
- Locations
- 🇰🇷
Incheon St. Mary's Hospital, Incheon, Korea, Republic of
Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT04639804
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT04309916
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 102
- Registration Number
- NCT04128917
- Locations
- 🇰🇷
Chung-Ang University Hosptial, Seoul, Korea, Republic of
Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 32
- Registration Number
- NCT04066257
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2020-04-08
- Target Recruit Count
- 291
- Registration Number
- NCT03591653
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT03378284
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 206
- Registration Number
- NCT02028663
- Locations
- 🇰🇷
Seoul National University Hospital and 11 others, Seoul, Korea, Republic of
Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT01473173
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.